The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Atherosclerosis

Treatments: Drug: MK0633

Study type: Interventional

Funder types: Industry

Identifiers

NCT00421278

MK0633-008

2006_563

0633-008

Details and patient eligibility

About

A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease

Enrollment: 180 patients

Sex: Male

Ages: 40 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease
• Inflammatory marker found in your blood, known as hsCRP > 0.5 mg/L

Exclusion criteria

• Age < 40 or > 85
• Female
• Heart attack, coronary artery bypass, stroke or unstable angina in last 3 months
• Liver diseased or abnormalities
• HIV infection
• Lupus, rheumatoid arthritis, cancer <5 years

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

180 participants in 1 patient group

1

Experimental group

Description:

Arm 1: Drug

Treatment:

Drug: MK0633